Unibest

Pharmaceutical intermediates

Belumosudil mesylate Intermediates

4 pharmaceutical intermediates for Belumosudil mesylate. Indication: graft-versus-host disease.

提交项目All intermediates

About Belumosudil mesylate

Originator
Nabriva Therapeutics Plc; Kadmon Corporation Llc
Indication
graft-versus-host disease
Approved Date
07/16/2021
NCE Patent
07/16/2026
DS/DP
10/30/2029

Available intermediates

4 intermediates currently listed for Belumosudil mesylate. Request specifications, documentation or a quotation for any item below.

Belumosudil mesylate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-bromo-N-isopropylacetamide75726-96-4//
1-BOC-5-AMINO-INDAZOLE129488-10-4//
Phenol, 3-(4-chloro-2-quinazolinyl)-, 1-acetate911417-24-8//
5-AMINOINDAZOLE19335-11-6//

Other programs under B

Baloxavir MarboxilBaricitinibBDTX-1535Bedaquiline FumarateBelzutifanBempedoic acidBeraprost SodiumBictegravir

Building toward Belumosudil mesylate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →